Adverse effects of antiseizure medications: a review of the impact of pharmacogenetics and drugs interactions in clinical practice
Authors:
Top Cited Papers
Open Access
- 10 July 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1584566
Abstract
Epilepsy is a chronic and debilitating neurological disorder characterized by the occurrence of spontaneous and recurrent seizures. Despite the availability of several antiseizure medications (ASMs), people with epilepsy often experience drug resistance and adverse effects. This narrative review provides an overview of the main adverse drug reactions (ADR) caused by ASMs, including neurological, metabolic, skin reactions and drug failure, and of the underlying molecular mechanisms. Given the critical contribution of pharmacogenomics and drug-drug interactions to the occurrence of some ADRs, we provide examples of the role of major allelic variations identified in genes encoding for molecules involved in the pharmacokinetics, pharmacodynamics and immune system and emphasize the activity of ASMs as inhibitors or inducers of metabolic enzymes. Improved knowledge of the benefit-risk profile of drugs, also through enhanced pharmacovigilance activity and following guidelines recommendations, could implement patients care avoiding ADRs and favoring a beneficial personalized medicine particularly in vulnerable patients as children, elderly people and pregnant women.Keywords
This publication has 94 references indexed in Scilit:
- Risk of Major Congenital Malformations and Exposure to Antiseizure Medication MonotherapyJAMA Neurology, 2024
- Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first‐line add‐on therapies for seizures in Dravet syndrome: A network meta‐analysisEpilepsia Open, 2024
- The pharmacological treatment of epilepsy in adultsEpileptic Disorders, 2023
- Pharmacological aspects of antiseizure medications: From basic mechanisms to clinical considerations of drug interactions and use of therapeutic drug monitoringEpileptic Disorders, 2023
- A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy SubjectsClinical Pharmacology in Drug Development, 2019
- HLA Alleles and CYP2C9*3 as Predictors of Phenytoin Hypersensitivity in East AsiansClinical Pharmacology & Therapeutics, 2018
- Genetic Variants Associated With Phenytoin-Related Severe Cutaneous Adverse ReactionsJAMA, 2014
- Relationship Between theHLA-B*1502Allele and Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisJAMA Dermatology, 2013
- Safety aspects of antiepileptic drugs—focus on pharmacovigilancePharmacoepidemiology and Drug Safety, 2011
- Functional characterization of an episodic ataxia type-1 mutation occurring in the S1 segment of hKv1.1 channelsPflügers Archiv - European Journal of Physiology, 2003